Stéphane Bancel

Director & Chief Executive Officer at Moderna, Inc.

Stéphane Bancel

Stéphane Bancel

Director & Chief Executive Officer at Moderna, Inc.

Overview
Career Highlights

Eli Lilly & Company
Moderna, Inc.
Modernatx, Inc.

RelSci Relationships

4061

Number of Boards

10

Birthday

1973

Age

47

Number of Awards

4
Relationships
View Relationship Details
RelSci Relationships are individuals Stéphane Bancel likely has professional access to. A relationship does not necessarily indicate a personal connection.
Noubar Afeyan

Co-Founder at Moderna, Inc.

Relationship likelihood: Strong

Robert Langer

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Douglas Cole

Founder at Foghorn Therapeutics, Inc.

Relationship likelihood: Strong

John D. Mendlein

Founder at Fate Therapeutics, Inc.

Relationship likelihood: Strong

Stephen Berenson

Managing Partner at Flagship Pioneering

Relationship likelihood: Strong

Stephen Hoge

President at Moderna, Inc.

Relationship likelihood: Strong

Geoffrey von Maltzahn

Co-Founder at Indigo Ag, Inc.

Relationship likelihood: Strong

Stephen W. Harbin

Chief of Staff & Chief Sustainability Officer at Modernatx, Inc.

Relationship likelihood: Strong

Elizabeth Nabel

President at The Brigham & Women's Hospital, Inc.

Relationship likelihood: Strong

Melissa Moore

Chief Scientific Officer at Modernatx, Inc.

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
In The News
Business Insider
November 25, 2020
Your complete coronavirus vaccine calendar: When candidates are likely to get authorized, and when you could receive your shot
Business Wire
November 25, 2020
Moderna Announces the European Commission's Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273); Option granted to European Commission to purchase up to an additional 80 million doses; Agreement
Nasdaq
November 25, 2020
330 Million Reasons to Buy Moderna Stock Right Now
The Independent UK
November 24, 2020
Russia’s two-shot Sputnik V Covid vaccine to cost less than $20
Business Standard India
November 24, 2020
European Union secures 160 million doses of Moderna's Covid-19 vaccine
Trending People
Chris Matthews
Chris Matthews, MSNBC host of 'Hardball,' quits on air after several controversi... - Washington Post Blogs
Mark Joseph Carney
The Latest: France shuts about 120 schools over virus - Associated Press
Ali Khamenei
Net group says Wikipedia disrupted in Iran amid coronavirus - Associated Press
Benjamin Netanyahu
Israeli exit polls: Netanyahu ahead, but short of majority - Associated Press
Tedros Adhanom Ghebreyesus
Virus alarms sound worldwide, but China sees crisis ebbing - Associated Press
Trending People
Chris Matthews
Chris Matthews, MSNBC host of 'Hardball,' quits on air after several controversi... - Washington Post Blogs
Mark Joseph Carney
The Latest: France shuts about 120 schools over virus - Associated Press
Ali Khamenei
Net group says Wikipedia disrupted in Iran amid coronavirus - Associated Press
Benjamin Netanyahu
Israeli exit polls: Netanyahu ahead, but short of majority - Associated Press
Tedros Adhanom Ghebreyesus
Virus alarms sound worldwide, but China sees crisis ebbing - Associated Press
Paths to Stéphane Bancel
Potential Connections via
Relationship Science
You
Stéphane Bancel
Director & Chief Executive Officer at Moderna, Inc.
Education
M.B.A.
Class of 2000
Harvard University - Harvard Business School

Harvard Business School (HBS) is the graduate business school of Harvard University in Boston, Massachusetts, United States. The school offers a large full-time MBA program, doctoral programs, and many executive education programs. It owns Harvard Business School Publishing, which publishes business books, leadership articles, online management tools for corporate learning, case studies, and the monthly Harvard Business Review.

Master of Engineering
Class of 1995
École Centrale Paris

Since its foundation in 1829, the École Centrale Paris has followed the same calling: training engineers capable of meeting the greatest challenges of their era. The challenge is to allow the 9 billion people who will live on our planet in 2050 to have access to water, food, energy, health, education, information, etc. To appreciate and meet the great challenges of the 21st century, the world needs ever more engineers – “three- dimensional” engineers: high level scientific and technical generalists, experts in initiating and piloting innovative projects and with a strong international culture. It is these new scientific leaders, entrepreneurs and innovators, that Centrale Paris seeks to train and to prepare for the companies, governments and institutions of today and tomorrow. These men and women will know how to respond to the issues of their age using the science and technology.

Master of Science in Chemical Engineering
University of Minnesota

The University of Minnesota, Twin Cities (Minnesota, U of M, or The U) is a public research university located in Minneapolis and St. Paul, Minnesota, United States, with the Minneapolis and St. Paul campuses being approximately 5 miles (8.0 km) apart. It is the oldest and largest campus within the University of Minnesota system and has the sixth-largest main campus student body in the United States, with 51,853 students in 2012–2013. The university is broadly organized into 19 colleges and schools, and it has sister campuses in Crookston, Duluth, Morris, and Rochester.

Unknown
CentraleSupélec Exed SA

CentraleSupélec operates as a higher education and research institution. The firm is a public institution under ministerial charter, devoted to the sciences and engineering. The company was founded on January 1, 2015 and is headquartered in Paris, France.

Career History
Venture Partner
2013 - Current
Flagship Pioneering

Flagship Pioneering seeks investment opportunities in companies located globally. The firm focuses on companies operating in the fields of therapeutics, life science tools & diagnostics, and bioenergy or cleantech. It provides financing for seed, early, and later-stage capital requirements. It acts as a lead investor. It also makes co-investments.

Chief Executive Officer
2006 - 2011
bioMérieux SA

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The firm develops testing. detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.

Professional
Prior
Eli Lilly & Co. Ltd.

Eli Lilly & Co. Ltd. provides pharmaceutical health care solutions. It provide products for cardiovascular, dermatology, diabetes, endocrine, musculoskeletal, neuroscience, oncology and urology. The company was incorporated on April 9, 1963 and is headquartered in Basingstoke, the United Kingdom.

Boards & Committees
Member, Board of Directors
2020 - Current
Indigo Ag, Inc.

Indigo Agriculture, Inc. provides microbial solutions. The firm offers platform for microbiome product discovery and has generated a robust pipeline of candidates for seed, soil, and foliar applications in globally important crops, including corn, soy, wheat, cotton, and vegetables The company was founded by Noubar Afeyan, David A. Berry, and Geoffrey von Maltzahn in 2014 and is headquartered in Boston, MA.

Supervisory Director
2013 - Current
Qiagen N.V.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Director & Chief Executive Officer
2011 - Current
Moderna, Inc.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Member, Board of Trustees
Current
Museum of Science - Boston

Museum of Science operates as a museum. The company was founded in 1830 and is headquartered in Boston, MA.
Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$25K +
2019
Epiphany School - Dorchester

The Epiphany School, Inc. provides education services. The company is headquartered in Dorchester, MA.

$5,000 - $10K
2019
The Posse Foundation, Inc.

POSSE STARTED BECAUSE OF ONE STUDENT WHO SAID, "I NEVER WOULD HAVE DROPPED OUT OF COLLEGE IF I HAD MY POSSE WITH ME." THE POSSE FOUNDATION, FOUNDED IN 1989, IDENTIFIES PUBLIC HIGH SCHOOL STUDENTS WITH EXTRAORDINARY ACADEMIC AND LEADERSHIP POTENTIAL WHO MAY BE OVERLOOKED BY TRADITIONAL COLLEGE SELECTION PROCESSES. THE FOUNDATION EXTENDS TO THESE STUDENTS THE OPPORTUNITY TO PURSUE PERSONAL AND ACADEMIC EXCELLENCE BY PLACING THEM IN SUPPORTIVE, MULTICULTURAL TEAMS ("POSSES") OF 10 STUDENTS. THE FOUNDATION'S PARTNER UNIVERSITIES AWARD POSSE SCHOLARS FOUR-YEAR, FULL-TUITION LEADERSHIP SCHOLARSHIPS.

$25K +
2018
Epiphany School - Dorchester

The Epiphany School, Inc. provides education services. The company is headquartered in Dorchester, MA.

Transactions
Details Hidden

Moderna, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Awards & Honors
2017
Ernst & Young - Entrepreneur of the Year New England
Rank #1
2011
Thomson Reuters Pan European EXTEL Study - CEO in the Biotechnology Sector
2009
World Economic Forum - Young Global Leaders
Other Affiliations

Stéphane Bancel is affiliated with Flagship Pioneering, bioMérieux SA, Eli Lilly & Co. Ltd., Modernatx, Inc., Eli Lilly & Company, ELI Lilly Benelux SA, Moderna, Inc., Indigo Ag, Inc., Qiagen N.V., Moderna, Inc., Modernatx, Inc., QIAGEN GmbH, Syros Pharmaceuticals, Inc., Targanta Therapeutics Corp., BG Medicine, Inc., Targanta Therapeutics, Inc., Museum of Science - Boston

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stéphane Bancel. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stéphane Bancel's profile does not indicate a business or promotional relationship of any kind between RelSci and Stéphane Bancel.